Skip to main content
    1

    10X Genomics Inc (TXG)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $56.30
    +1.31 (+2.38%)

    Market Cap: $7.23B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    10X Genomics Inc (TXG) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    10X Genomics (TXG) has a market cap of $7.23B and an enterprise value of $6.71B. Its share count is up 4.23% from a year earlier. It kept -10.84% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 7.27% below the market cap, as cash exceeds debt.

    Market Cap$7.23B
    Enterprise Value$6.71B
    Latest price (Nov 17, 2026)$56.30

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.63% in the quarter ended Sep 30, 2026 and grew 4.09% a year over 2 years.

    Shares Outstanding130.81M
    Shares Change (YoY)+4.23%
    Shares Change (QoQ)+0.63%
    Share Count Growth (2Y CAGR)+4.09%

    Valuation Ratios

    Sales and book value multiples are 11.9x and 8.8x. Its year-end P/S ranged from 2.8x to 48.3x from 2019 to 2025.

    P/S Ratio11.9x
    Forward P/S11.5x
    P/B Ratio8.8x
    P/TBV Ratio9.5x
    P/FCF Ratio78.5x
    P/OCF Ratio72.5x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 72.9x free cash flow.

    EV / Sales10.8x
    EV / FCF72.9x

    Price Statistics

    The stock is up 254.31% over 52 weeks and trades 23.48% below its 50-day average.

    Beta (1Y)2.48
    52-Week Change+254.31%
    1-Month Change-19.44%
    3-Month Change-9.47%
    6-Month Change+152.58%
    5-Year Change-56.53%
    Total Return (1Y)+254.31%
    Total Return (3Y CAGR)+10.11%
    Total Return (5Y CAGR)-17.78%
    Return vs SPY (1Y)+250.27%
    Max Drawdown (1Y)-43.74%
    Max Drawdown (3Y)-87.59%
    Sharpe Ratio (1Y)1.70
    Correlation with SPY (1Y)0.45
    50-Day Average$73.58
    200-Day Average$42.93
    52-Week Range$15.18 to $102.81
    RSI (14 Days)38.5
    Average Volume (20 Days)3.22M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.12x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.12x
    Quick Ratio4.66x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -8.00% over the last 12 months, against a 5-year average of -18.67%.

    Return on Equity (ROE)-8.00%
    Return on Assets (ROA)-6.31%
    ROE (5Y Average)-18.67%
    ROA (5Y Average)-14.47%
    ROIC (5Y Average)-7.53%
    Asset Turnover0.59x
    Inventory Turnover2.97x
    Receivables Turnover11.31x
    Cash Conversion Cycle111 days

    Scores

    TXG has an Altman Z-Score of 18.54, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score18.54
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $618.58M over the last 12 months is down 3.62% from the 12 months before.

    Revenue$618.58M
    Revenue Growth (YoY)-3.62%
    Gross Profit$444.65M
    Operating Income-$72.20M
    Pretax Income-$65.16M
    Net Income-$67.08M
    EBITDA-$43.70M
    Reported EPS (TTM)-$0.15

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.06% of the $1.06B in total assets.

    Cash and Equivalents$526.19M
    Total Debt$0
    Net Cash$526.19M
    Net Cash Per Share$4.02
    Working Capital$578.26M
    Shareholder Equity$838.04M
    Book Value Per Share$6.41
    Tangible Book Value$772.46M
    Tangible Book Per Share$5.91
    Total Assets$1.06B
    Total Liabilities$225.09M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.93M of capital spending, operating cash flow left $93.77M of free cash flow.

    Operating Cash Flow$99.70M
    Capital Expenditures$5.93M
    Free Cash Flow$93.77M
    FCF Per Share$0.78
    Depreciation and Amortization$43.18M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -11.67%, against a 5-year average of -25.48%.

    Gross Margin71.88%
    Operating Margin-11.67%
    Pretax Margin-10.53%
    Net Margin-10.84%
    EBITDA Margin-7.07%
    FCF Margin15.16%
    Gross Margin (5Y Average)72.93%
    Operating Margin (5Y Average)-25.48%
    Net Margin (5Y Average)-24.38%

    Growth

    Revenue grew 7.57% a year over 3 years.

    Revenue Growth (3Y CAGR)+7.57%
    Revenue Growth (5Y CAGR)+16.55%
    Book Value Per Share Growth (2Y CAGR)+0.13%
    Tangible Book Per Share Growth (2Y CAGR)-2.77%

    Revenue and profit by year

    Dividends and Yields

    TXG does not pay a dividend. Its free cash flow yield is 1.27%.

    FCF Yield1.27%
    Buyback Yield-0.19%
    Shareholder Yield-0.19%

    Peer Position

    Against 11 similar companies, TXG has the highest P/S.

    P/S Ratio11.9x vs 3.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)-3.62% vs +7.91% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.72% and EPS growth at -38.60% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.72%
    EPS Growth Forecast (2Y CAGR)-38.60%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TXG

    What is TXG's market cap?

    10X Genomics has a market cap of $7.23B. Its enterprise value, which adds debt and subtracts cash, is $6.71B.

    How many shares of TXG are outstanding?

    10X Genomics has 130.81M shares outstanding. The count is up 4.23% from a year earlier.

    Does TXG pay a dividend?

    No. 10X Genomics does not pay a dividend.

    How much debt does TXG have?

    10X Genomics has $0 of total debt and $526.19M of cash and equivalents, a net cash position of $526.19M.